Holen Sie sich die Stockscreener-App
10.94
1.17%
-0.13
Schlusskurs vom Vortag:
$11.07
Offen:
$11.29
24-Stunden-Volumen:
1.57M
Relative Volume:
1.13
Marktkapitalisierung:
$628.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.79M
KGV:
-14.05
EPS:
-0.7789
Netto-Cashflow:
$-53.49M
1W Leistung:
-6.17%
1M Leistung:
-27.31%
6M Leistung:
+66.77%
1J Leistung:
+436.27%
1-Tages-Spanne:
$10.73
$11.29
1-Wochen-Bereich:
$10.73
$11.93
52-Wochen-Spanne:
$1.54
$18.33
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
10.94 | 669.71M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Mizuho | Outperform |
| 2026-03-24 | Eingeleitet | B. Riley Securities | Buy |
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-03-05 | Eingeleitet | Wedbush | Outperform |
| 2026-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | William Blair | Outperform |
| 2025-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-06-06 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Nigeria
Options for 70,000 shares were exercised at $1.29–$7.89 in Climb Bio (CLYM). - Stock Titan
Raymond James adds Climb Bio stock to favorites list on drug potential - Investing.com Canada
Climb Bio, Inc.(NasdaqGM: CLYM) added to S&P Biotechnology Select Industry Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to S&P Global BMI Index - marketscreener.com
Director Stephen Thomas Sells 100,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio (CLYM) director sells 100K shares in preset plan - Stock Titan
CLYM: CLYM116 and budoprutug advance with best-in-class data, Q12-week dosing, and pivotal trials ahead - TradingView
CLYM: CLYM116 and budoprutug advance with best-in-class profiles and key data readouts expected soon - TradingView
Climb Bio (NASDAQ: CLYM) director files to sell insider stake - Stock Titan
CLYM Stock Price, Quote & Chart - ChartMill
Climb Bio presents initial Phase 1 data for CLYM116 - Traders Union
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com Nigeria
H.C. Wainwright raises Climb Bio stock price target on drug data By Investing.com - Investing.com Australia
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Australia
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - Moomoo
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com Canada
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40 - Moomoo
symbol__ Stock Quote Price and Forecast - cnn.com
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Phreesia (PHR) - The Globe and Mail
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Canada
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data By Investing.com - Investing.com South Africa
BTIG raises Climb Bio stock price target to $32 on phase 1 data By Investing.com - Investing.com South Africa
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug - Yahoo Finance
Climb Bio Announces Positive Phase 1 Trial Outcomes for CLYM116 Targeting IgA Nephropathy - Kalkine Media
Baird Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $25 - Moomoo
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule - Benzinga
Climb Bio rises on trial data for kidney drug (CLYM:NASDAQ) - Seeking Alpha
CLYM: CLYM116 shows robust, durable APRIL and IgA suppression with a favorable safety profile in phase I - TradingView
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data - Yahoo Finance
Why is Climb Bio stock sliding today? By Investing.com - Investing.com Canada
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data - TipRanks
Climb Bio stock surges 17% on positive drug trial results - Investing.com
Climb Bio stock surges 17% on positive drug trial results By Investing.com - Investing.com India
Climb Bio reports phase 1 data for IgA nephropathy drug By Investing.com - Investing.com Nigeria
Climb Bio reports phase 1 data for IgA nephropathy drug - investing.com
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating - globenewswire.com
Climb Bio to Present at Upcoming Investor Conferences - markets.businessinsider.com
Climb Bio Stock Up In Pre-Market Ahead Of CLYM116 Data Tomorrow - RTTNews
Climb Bio Inc. (CLYM) Holds Gains: Stock Trades at $13.9 as $14.6 Resistance Caps UpsidePrice Momentum Stocks - dars.gov.et
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Climb Bio Inc-Aktie (CLYM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomas Stephen Basil | Director |
Sep 15 '26 |
Sale |
13.67 |
100,000 |
1,366,820 |
467,969 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):